bevacizumab + capecitabine + everolimus + oxaliplatin

This is a combination regimen consisting of four agents—bevacizumab, capecitabine, everolimus, and oxaliplatin—used in the treatment of advanced or metastatic solid tumors, particularly metastatic colorectal cancer (mCRC). - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply. - **Capecitabine** is an oral prodrug converted to 5-fluorouracil (5-FU) in the body; it acts as an antimetabolite inhibiting DNA synthesis in rapidly dividing cells. - **Everolimus** is an mTOR inhibitor that blocks cell proliferation and angiogenesis by inhibiting the mammalian target of rapamycin pathway. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in cancer cells. This combination has been studied primarily for its efficacy and safety profile in patients with advanced or refractory colorectal cancer. Clinical trials have shown activity but also significant toxicity at full doses; dose adjustments are often required[6]. The regimen leverages multiple mechanisms to target tumor growth through cytotoxicity, antiangiogenesis, and inhibition of cellular signaling pathways[1][2][6].

Brand names

XelodaEloxatinAvastinAfinitor

Other names

XELOX (for capecitabine + oxaliplatin)CAPOX (for capecitabine + oxaliplatin)